tradingkey.logo
tradingkey.logo
Search

Centessa Pharmaceuticals PLC

CNTA
Add to Watchlist
40.500USD
0.0000.00%
Market hours ETQuotes delayed by 15 min
6.27BMarket Cap
LossP/E TTM

TradingKey Stock Score of Centessa Pharmaceuticals PLC

Currency: USD Updated: 2026-06-23

Key Insights

Centessa Pharmaceuticals PLC's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 49 out of 389 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 43.57.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Centessa Pharmaceuticals PLC's Score

Industry at a Glance

Industry Ranking
49 / 389
Overall Ranking
126 / 4573
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Centessa Pharmaceuticals PLC Highlights

StrengthsRisks
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 118.88% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 15.00M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 15.00M.
Undervalued
The company’s latest PE is -22.82, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 150.25M shares, increasing 7.40% quarter-over-quarter.
Held by Lee Ainslie
Star Investor Lee Ainslie holds 1.85M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.37.

Analyst Rating

Based on 6 analysts
Hold
Current Rating
42.500
Target Price
+4.94%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

How does TradingKey generate the Stock Score of Centessa Pharmaceuticals PLC?

The TradingKey Stock Score provides a comprehensive assessment of Centessa Pharmaceuticals PLC based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Centessa Pharmaceuticals PLC’s performance and outlook.

How do we generate the financial health score of Centessa Pharmaceuticals PLC?

To generate the financial health score of Centessa Pharmaceuticals PLC, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Centessa Pharmaceuticals PLC's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Centessa Pharmaceuticals PLC.

How do we generate the company valuation score of Centessa Pharmaceuticals PLC?

To generate the company valuation score of Centessa Pharmaceuticals PLC, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Centessa Pharmaceuticals PLC’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Centessa Pharmaceuticals PLC’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Centessa Pharmaceuticals PLC.

How do we generate the earnings forecast score of Centessa Pharmaceuticals PLC?

To calculate the earnings forecast score of Centessa Pharmaceuticals PLC, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Centessa Pharmaceuticals PLC’s future.

How do we generate the price momentum score of Centessa Pharmaceuticals PLC?

When generating the price momentum score for Centessa Pharmaceuticals PLC, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Centessa Pharmaceuticals PLC’s prices. A higher score indicates a more stable short-term price trend for Centessa Pharmaceuticals PLC.

How do we generate the institutional confidence score of Centessa Pharmaceuticals PLC?

To generate the institutional confidence score of Centessa Pharmaceuticals PLC, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Centessa Pharmaceuticals PLC’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Centessa Pharmaceuticals PLC.

How do we generate the risk management score of Centessa Pharmaceuticals PLC?

To assess the risk management score of Centessa Pharmaceuticals PLC, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Centessa Pharmaceuticals PLC’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Centessa Pharmaceuticals PLC.
KeyAI